Bolt Biotherapeutics (BOLT) Share-based Compensation (2020 - 2026)
Bolt Biotherapeutics (BOLT) posted Share-based Compensation of $545000.0 for Q1 2026, down 47.65% sequentially from $1.0 million in Q4 2025, and down 23.13% YoY from $709000.0 in Q1 2025.
Bolt Biotherapeutics (BOLT) Share-based Compensation (2020 - 2026) Analysis & Trends
Bolt Biotherapeutics has reported Share-based Compensation for 7 years, with the latest figure at $545000.0 in Q1 2026.
- Quarterly Share-based Compensation fell 23.13% year-over-year to $545000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.6 million (down 45.56% YoY) and the FY2025 annual result came in at $2.8 million, down 56.54% from the prior year.
- Share-based Compensation fell to $545000.0 in Q1 2026 per BOLT's latest filing, from $1.0 million in the prior quarter.
- Over five years, Share-based Compensation peaked at $2.9 million in Q1 2022 and troughed at -$7.2 million in Q4 2023.
- A 5-year average of $1.1 million and a median of $2.1 million in 2022 frame the typical range for Share-based Compensation.
- The sharpest annual moves came in 2023 and 2025: Share-based Compensation sank 437.02% in 2023, then jumped 488.14% in 2025.
- Over 5 years, Share-based Compensation stood at $2.1 million in 2022, then tumbled by 437.02% to -$7.2 million in 2023, then soared by 102.47% to $177000.0 in 2024, then surged by 488.14% to $1.0 million in 2025, then slumped by 47.65% to $545000.0 in 2026.
- According to Business Quant data, Share-based Compensation over the past three periods registered $545000.0, $1.0 million, and $407000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 86.63 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 41.25 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 28.05 Mn |
| 10 | Bolt Biotherapeutics | 5.48 Mn | 5.48 Mn | - | 552,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 552,000.00 |
| Jun 30, 2026 | 552,000.00 |
| Mar 31, 2026 | 545,000.00 |
| Mar 31, 2026 | 545,000.00 |
| Dec 31, 2025 | 1.04 Mn |
| Dec 31, 2025 | 1.04 Mn |
| Sep 30, 2025 | 407,000.00 |
| Sep 30, 2025 | 407,000.00 |
| Jun 30, 2025 | 625,000.00 |
| Jun 30, 2025 | 625,000.00 |
| Mar 31, 2025 | 709,000.00 |
| Mar 31, 2025 | 709,000.00 |
| Dec 31, 2024 | 177,000.00 |
| Dec 31, 2024 | 177,000.00 |
| Sep 30, 2024 | 1.10 Mn |
| Sep 30, 2024 | 1.10 Mn |
| Jun 30, 2024 | 2.83 Mn |
| Jun 30, 2024 | 2.83 Mn |
| Mar 31, 2024 | 2.30 Mn |
| Mar 31, 2024 | 2.30 Mn |